Clinical Trials Logo

Filter by:
NCT ID: NCT06276556 Enrolling by invitation - Gout Clinical Trials

Extension Study of ABP-671 in Participants With Gout

Start date: April 22, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3).

NCT ID: NCT06272734 Recruiting - Clinical trials for Acute Decompensated Heart Failure

Reprieve System Pilot Study

Start date: January 23, 2024
Phase: N/A
Study type: Interventional

The objective of the study is to evaluate the use of the Reprieve System to decongest subjects with acute decompensated heart failure.

NCT ID: NCT06249529 Recruiting - Emphysema or COPD Clinical Trials

Airway Bypass - Safety and Feasibility Study

AIRWAY
Start date: January 26, 2024
Phase: Early Phase 1
Study type: Interventional

The objective of this study is to evaluate its safety and feasibility of the Airway Bypass Stent System in patients with severe emphysema. The study will collect clinical data through 12 months to assess procedural and device safety.

NCT ID: NCT06219941 Recruiting - Gastric Cancer Clinical Trials

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Start date: December 13, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.

NCT ID: NCT06208215 Recruiting - Clinical trials for Congenital Hyperinsulinism

RZ358 Treatment for Congenital Hyperinsulinism

sunRIZE
Start date: January 11, 2024
Phase: Phase 3
Study type: Interventional

The Phase 3 pivotal study is designed to evaluate the efficacy and safety of RZ358 for the treatment of congenital hyperinsulinism (HI) as add-on to standard-of-care (SOC) therapy compared to SOC alone over 24 weeks and to evaluate the longer-term safety and efficacy of RZ358 during a subsequent open-label extension (OLE) period.

NCT ID: NCT06207227 Completed - Vaginal Atrophy Clinical Trials

Clinical Performance and Safety of the VITA AV Clinical System

Start date: April 13, 2023
Phase: N/A
Study type: Interventional

The primary objective of this clinical investigation is to demonstrate that treatment with the VITA AV clinical system is feasible and to evaluate clinical performance and safety when used to improve the symptoms and signs of vaginal atrophy (VA) due to menopause.

NCT ID: NCT06154330 Recruiting - Clinical trials for Glaucoma, Open-Angle

Safety and Efficacy of Suprachoroidal Tube Shunt in Patients With Primary Open and Pseudoexfoliation Glaucomas

Start date: November 20, 2023
Phase:
Study type: Observational

To assess safety and efficacy of a novel suprachoroidal silicone tube (SST) shunt for the treatment of primary open angle and exfoliative glaucomas.

NCT ID: NCT06137820 Active, not recruiting - Clinical trials for Ankle Injury or Chronic Trauma to the Ankle

CETI-ANKLE: Cetilar®️ in Patients With Ankle Injury or Chronic Trauma to the Ankle

Start date: November 18, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and efficacy of Cetilar®

NCT ID: NCT06134115 Completed - Clinical trials for Primary Knee Osteoarthritis Grade 3 - 4

LIKEST Study: Lipocet® in Adults With Primary Knee Osteoarthritis Grade 3-4

Start date: August 19, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and efficacy of Lipocet® (food supplement) in patients with primary knee osteoarthritis grade 3 - 4

NCT ID: NCT06103539 Not yet recruiting - Clinical trials for Heart Failure With Reduced Ejection Fraction

Pacertool Early Feasibility Study - Safety and Performance

Start date: December 1, 2023
Phase:
Study type: Observational

The study is a non-randomized, two-part, open label, prospective single-site, single arm, safety and performance study. The study is designed to collect acute and long-term clinical data and user reported outcome data from using the PreSens-Catheter and PACER Software during cardiac catheterization and Cardiac Resynchronization Therapy (CRT) device implantation procedures. Subjects with indication for arterial catheterization and CRT will be included.